Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026)
Novartis Ag's Other Accumulated Expenses was $15.32 billion in Q2 2026, down 3.1% from $15.81 billion a year earlier and down 11.8% from the prior quarter.
Powered by 
Analysis
Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026) Analysis & Trends
At the end of FY2025, Other Accumulated Expenses at Novartis Ag came in at $14.99 billion, up 6.6% from FY2024.
- Other Accumulated Expenses shows a five-year compound annual growth rate of -0.2% (FY2020 to FY2025).
- In earlier years, Other Accumulated Expenses was $14.05 billion in FY2024 (+6.7%), $13.17 billion in FY2023 (-11.0%), $14.8 billion in FY2022 and $619 million in FY2021 (-95.9%).
- Quarterly Other Accumulated Expenses has moved between $619 million (Q4 2021) and $17.36 billion (Q1 2026) over five years.
- Compared with a year earlier, Other Accumulated Expenses was higher in seven of the last eight quarters, with growth averaging 7.0%.
- The best year-over-year quarter for Other Accumulated Expenses over five years was Q1 2022 (growth of 695.0%); the worst was Q4 2021 (a decline of 95.9%).
- Per Business Quant data, NVS's Other Accumulated Expenses in the three quarters before Q2 2026 was $17.36 billion (Q1 2026), $14.99 billion (Q4 2025) and $16.32 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.58 Bn | 1,078.16 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 630.16 Bn | 548.69 Bn | 17.26 Bn |
| 3 | AbbVie | 488.57 Bn | 461.73 Bn | 12.70 Bn |
| 4 | Merck | 359.15 Bn | 313.58 Bn | 12.21 Bn |
| 5 | Novartis Ag | 274.32 Bn | 238.71 Bn | 11.24 Bn |
| 6 | Astrazeneca | 246.73 Bn | 220.50 Bn | 12.86 Bn |
| 7 | Amgen | 224.28 Bn | 179.68 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 187.60 Bn | 161.71 Bn | 6.22 Bn |
| 9 | Pfizer | 161.13 Bn | 108.08 Bn | 10.94 Bn |
| 10 | Vertex Pharmaceuticals | 129.23 Bn | 101.23 Bn | 2.84 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.32 Bn |
| Mar 31, 2026 | 17.36 Bn |
| Dec 31, 2025 | 14.99 Bn |
| Sep 30, 2025 | 16.32 Bn |
| Jun 30, 2025 | 15.81 Bn |
| Mar 31, 2025 | 16.75 Bn |
| Dec 31, 2024 | 14.05 Bn |
| Sep 30, 2024 | 15.07 Bn |
| Jun 30, 2024 | 13.78 Bn |
| Mar 31, 2024 | 15.01 Bn |
| Dec 31, 2023 | 13.17 Bn |
| Sep 30, 2023 | 13.97 Bn |
| Jun 30, 2023 | 15.34 Bn |
| Mar 31, 2023 | 14.94 Bn |
| Dec 31, 2022 | 14.80 Bn |
| Sep 30, 2022 | 13.48 Bn |
| Jun 30, 2022 | 12.93 Bn |
| Mar 31, 2022 | 15.18 Bn |
| Dec 31, 2021 | 619.00 Mn |
| Sep 30, 2021 | 13.14 Bn |
API Access
Novartis Ag Other Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=NVS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "other-accumulated-expenses", "ticker": "NVS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=NVS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();